Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
Research output: Contribution to journal › Review › Research › peer-review
Standard
Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease. / Borkar, Nrupa; Mu, Huiling; Holm, René.
In: Asian Journal of Pharmaceutical Sciences, Vol. 13, No. 6, 01.11.2018, p. 507-517.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
AU - Borkar, Nrupa
AU - Mu, Huiling
AU - Holm, René
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Parkinson's disease (PD) is a chronic debilitating disease affecting approximately 1% of the population over the age of 60. The severity of PD is correlated to the degree of dopaminergic neuronal loss. Apomorphine has a similar chemical structure as the neurotransmitter dopamine and has been used for the treatment of advanced PD patients. In PD patients, apomorphine is normally administered subcutaneously with frequent injections because of the compound's extensive hepatic first-pass metabolism. There is, hence, a large unmet need for alternative administrative routes for apomorphine to improve patient compliance. The present review focuses on the research and development of alternative delivery of apomorphine, aiming to highlight the potential of non-invasive apomorphine therapy in PD, such as sublingual delivery and transdermal delivery.
AB - Parkinson's disease (PD) is a chronic debilitating disease affecting approximately 1% of the population over the age of 60. The severity of PD is correlated to the degree of dopaminergic neuronal loss. Apomorphine has a similar chemical structure as the neurotransmitter dopamine and has been used for the treatment of advanced PD patients. In PD patients, apomorphine is normally administered subcutaneously with frequent injections because of the compound's extensive hepatic first-pass metabolism. There is, hence, a large unmet need for alternative administrative routes for apomorphine to improve patient compliance. The present review focuses on the research and development of alternative delivery of apomorphine, aiming to highlight the potential of non-invasive apomorphine therapy in PD, such as sublingual delivery and transdermal delivery.
KW - Alternative apomorphine therapy
KW - Apomorphine
KW - Drug delivery
KW - Excipients
KW - Non-invasive delivery
KW - Parkinson's disease
U2 - 10.1016/j.ajps.2017.11.004
DO - 10.1016/j.ajps.2017.11.004
M3 - Review
AN - SCOPUS:85040508022
VL - 13
SP - 507
EP - 517
JO - Asian Journal of Pharmaceutical Sciences
JF - Asian Journal of Pharmaceutical Sciences
SN - 1818-0876
IS - 6
ER -
ID: 209526856